Johnson & Johnson and AbbVie look set for a continued pharma ad spending battle for the second half of 2026 as the U.S. Big Pharma’s immunology drug Tremfya took the top spot for a second quarter in a row, according to data from iSpot.tv.
Source: FiercePharma
